Navigation Links
Predicting survival after liver transplantation
Date:11/5/2007

Patients awaiting liver transplantation who also suffer from other medical problems may face poorer survival after transplantation. These comorbid problems, which include coronary disease, diabetes, chronic obstructive pulmonary disease (COPD), connective tissue disease and renal insufficiency, have been incorporated into a new modified comorbidity index which helps predict post-transplant survival. These findings are published in the November issue of Liver Transplantation, a journal by John Wiley & Sons. The article is also available online via Wiley Interscience (http://www.interscience.wiley.com/journal/livertransplantation).

Determining who receives the limited supply of donor organs is one of the greatest challenges facing the transplant community. Severity of illness is the main criteria for hopeful liver recipients, however it is not the only factor that influences post-transplant survival. In other medical fields, co-morbidities have been considered as relevant predictors of survival, but never among the liver transplant community.

To address this paucity in the literature, researchers, led by Michael Volk of the University of Michigan sought to determine if the Charlson Comorbidity Index (CCI) would predict long-term survival after liver transplantation.

They conducted a retrospective study of 624 patients who underwent liver transplantation at the University of Michigan Hospital between 1994 and 2005 (to obtain a median follow-up of 5 years). They collected demographic, clinical and laboratory data for each patient, but focused on the nine comorbidities comprising the Charlson Comorbidity Index. These include congestive heart failure, coronary artery disease, diabetes mellitus, peripheral vascular disease, cerebral vascular accident, COPD, connective tissue disease, renal insufficiency and malignancy.

Forty percent of the patients had one or more comorbidities prior to transplantation. After statistical analysis, the researchers found that coronary disease, diabetes, COPD, connective tissue disease, and renal insufficiency were all independent predictors of poorer post-transplant survival. The researchers then recalibrated the CCI using this information, to create the CCI-OLT. This new index predicted post-transplant survival as well or better than other available models which use recipient characteristics like age, race, BMI, and etiology of liver disease.

Our study shows that comorbidities play an important role in determining post-transplant survival, the authors report. This information will be useful when counseling patients with comorbidities about outcomes after transplantation.

The study was limited by the fact that it was a single center, retrospective cohort study, and the researchers were not able to determine to what extent the comorbidities were manifestations of advanced liver disease. Still, the researchers demonstrated the usefulness of the modified comorbidity index for predicting post-liver-transplant. In the future, they conclude, the addition of comorbidities to multivariable models may be useful in developing new allocation algorithms which incorporate the likelihood of post-transplant survival.

An accompanying editorial, by Richard Freeman of the New England Medical Center, lauds the authors for their novel approach, though he cautioned that it remains to be seen if these results can be replicated. He writes that it is also somewhat disappointing that the CCI-OLT index was no better at predicting outcome than most of the other models already published.

Still, he reports, the mathematical model present by Volk and colleagues, can help estimate ahead of time what might be correct choices for patients when the call comes in the middle of the night.


'/>"/>

Contact: Amy Molnar
amolnar@wiley.com
John Wiley & Sons, Inc.
Source:Eurekalert

Related medicine news :

1. Use of certain lipid measures not more effective in predicting coronary heart disease
2. Blood test takes step toward predicting Alzheimers risk, Stanford researchers find
3. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
4. Survival differences by race most apparent in advanced stages of breast cancer
5. Prophylactic cranial irradiation in small cell lung cancer significantly increases survival
6. Human C-reactive protein regulates myeloma tumor cell growth and survival
7. Mediterranean Diet May Boost Alzheimers Survival
8. Hospitals Improve Survival Rates While Treating Sicker Patients Thomson Healthcare Study Shows
9. The Fight for His Life: Author, Family Battle Disease and Challenge Politics in the Face of Survival
10. Communication in cancer world is key to survival
11. Molecular profiling can accurately predict survival in colon cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... The new knee compression sleeves ... to buy neoprene knee sleeves for lifting and any sport that requires ... on two main aspects to provide a higher quality knee sleeve performance. Firstly it ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... today that they have teamed up with The American College of Surgeons (ACS) ... ACS’s Committee on Trauma, the “Bleeding Control Basic” course is a pilot program ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... and many more tools allowing FCPX editors to create professional looking video in ... , Perfect Harmony contains a beautifully designed 3D environment for placing in ...
(Date:12/4/2016)... ... December 04, 2016 , ... "Pro3rd Displace ... animation styles with unique displacement design elements," said Christina Austin - CEO of ... Choose from a variety of design styles that include both left aligned and ...
(Date:12/2/2016)... ... 2016 , ... Halfway through its partnership with First 5 LA, Western University ... than 15,900 children 5 years old and younger and treatment services to more than ... of five years to Western University of Health Sciences, UCLA and USC, beginning March ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , December 5, 2016 PharmaBoardroom today releases ... . ... This report offers companies, investors, policymakers, and stakeholders crucial insight ... of Europe , home to some of the world,s ... pharmaceutical companies in Novartis and Roche, and with a number one ranking ...
(Date:12/5/2016)... VIENNA and TAIPEI, Taiwan , ... 12 months of treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea ... demonstrated a significantly better safety and tolerability profile of ropeginterferon ... data from PROUD-PV and the ongoing long-term follow-up trial CONTINUATION-PV ... PharmaEssentia intends to present this data to the ...
(Date:12/4/2016)... ORLEANS , Dec. 2, 2016  Former Attorney General ... Jr., Esq. , a partner at the law firm of ... commenced an investigation into Lannett Company, Inc. (NYSE: ... Bloomberg published an article titled "U.S. Charges in Generic-Drug ... "antitrust investigation by the Justice Department, begun about two years ...
Breaking Medicine Technology: